301087 Cofoe Medical Technology
- 38.15
- -0.03-0.08%
Cofoe Medical Technology News
Kefu Healthcare (301087.SZ) announced its 2023 annual results. Net profit of 254 million yuan decreased by 15.71% year-on-year
Kefu Healthcare (301087.SZ) released the 2023 annual performance report. The company achieved operating income of 2 during the reporting period...
Kefu Healthcare (301087.SZ): As of March 29, 2024, the total number of shareholders of the company was about 20,000
Gelonghui, April 3 | Kefu Healthcare (301087.SZ) said on the investor interactive platform that as of March 29, 2024, the total number of shareholders of the company was about 20,000.
Kefu Healthcare (301087.SZ) grants 6.33,000 restricted shares at a grant price of 16.6 yuan/share
Kefu Healthcare (301087.SZ) announced that the company's “2024 Restricted Stock Incentive Plan (Draft)” regulations...
Is Cofoe Medical TechnologyLtd (SZSE:301087) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Kefu Healthcare (301087.SZ) plans to grant 6.633 million restricted shares at an award price of 16.6 yuan/share
Kefu Healthcare (301087.SZ) disclosed the 2024 Restricted Stock Incentive Plan (draft), and the company plans to promote...
Cofoe Medical Technology Co.,Ltd. (SZSE:301087) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
It is hard to get excited after looking at Cofoe Medical TechnologyLtd's (SZSE:301087) recent performance, when its stock has declined 18% over the past three months. However, stock prices are usual
Kefu Medical (301087.SZ): Currently, the Jianer Hearing Testing Center has signed more than 800 contracts
On January 11, Ge Longhui Medical (301087.SZ) said during a survey by institutional investors that at present, Jianer Hearing Testing Center has signed more than 800 contracts, covering 19 provincial markets across the country, including over 100 in Hunan, Sichuan, Guangxi and Hubei. In the next 1-2 years, hearing and hearing will continue to expand at a high rate. We hope to complete the national layout in a short period of time, but the final opening of the store depends on the expansion team, personnel training, etc.
Kefu Medical (301087.SZ): At present, it has achieved independent production of core products such as blood pressure monitors, accounting for about 55% of the revenue
On January 11, Ge Longhui | Kefu Medical (301087.SZ) said during the reception of institutional investors that in 2023, the company promoted product restructuring and new product commissioning work at production bases in Changsha and Xiangyin in an orderly manner, continuously enriching the range of products produced independently and production capacity. At present, the company has achieved independent production of core products such as blood pressure monitors, blood sugar meters, thermometers, wheelchairs, nursing beds, oxygen concentrators, nebulizers, dressings, and masks, accounting for about 55% of the revenue from in-house production. With the increase in the scale of self-production, there is some room for improvement in the company's gross margin, and product quality will continue to improve, providing consumers with higher quality and more
Private Companies Who Own 47% Along With Institutions Invested in Cofoe Medical Technology Co.,Ltd. (SZSE:301087) Saw Increase in Their Holdings Value Last Week
Key Insights Cofoe Medical TechnologyLtd's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 3 investors have a
Kefu Healthcare (301087. SZ): Repurchased 2.01% of shares at a total cost of 156 million yuan
Gelonghui (301087.SZ) announced on December 1 | Kefu Healthcare (301087.SZ) announced that as of November 30, 2023, the company has repurchased 4202369 million shares of the company's shares through centralized bidding transactions through special repurchase securities accounts, accounting for 2.01% of the company's total share capital of 209,238,250 shares. The highest transaction price is 39.77 yuan/share, the lowest transaction price is 36.00 yuan/share, and the total transaction amount is 156 million yuan (excluding transaction fees).
Zhang Shaoda, the core technician of Kefu Medical (301087.SZ), resigned and added the certification of Quan Changyun as the core technician
Kefu Medical (301087.SZ) announced that Zhang Shaoda, the company's core technician, resigned from the relevant position due to personal reasons,...
Kefu Healthcare (301087. SZ): Repurchased 2.00% of shares at a cumulative cost of about 156 million yuan
Glonghui on October 31 | Kefu Healthcare (301087.SZ) announced that as of October 31, 2023, the company has repurchased a total of 4184769 million shares of the company's shares through centralized bidding transactions through special securities repurchase accounts, accounting for an increase in the company's total share capital (due to the increase in share capital due to the company's 2021 restricted stock incentive plan, the total number of shares of the company increased from 208,487,500 shares to 209,238,250 shares), with a maximum transaction price of 39.12 yuan/share , the lowest transaction price is 36.
About 1,396,500 restricted shares of Kefu Healthcare (301087.SZ) will be listed and distributed on October 25
Kefu Healthcare (301087.SZ) announced that the number of shareholders applying for the lifting of share sales restrictions this time is 1 (Western...
Kefu Healthcare (301087.SZ): Revenue from rehabilitation aids products increased by 22.54% year-on-year in the first half of the year
Glonghui, October 19丨Kefu Medical (301087.SZ) stated on the investor interaction platform that the company's manual wheelchairs and electric wheelchairs are classified as rehabilitation aids. In the first half of this year, the company's revenue from rehabilitation aids products increased by 22.54% year-on-year. Among them, the sales volume of wheelchair products increased well.
Cofoe Medical Technology Co.,Ltd.'s (SZSE:301087) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Cofoe Medical TechnologyLtd (SZSE:301087) has had a rough three months with its share price down 19%. However, the company's fundamentals look pretty decent, and long-term financials are usually ali
The repurchase ratio of Kefu Medical (301087.SZ) reached 1.89% and cost 146 million yuan
Kefu Healthcare (301087.SZ) announced that up to now, the company has repurchased a total of 3.942,900 shares, accounting for...
Kefu Healthcare (301087.SZ): By the end of August, nearly 700 hearing testing centers had been signed and nearly 600 had been opened
Glonghui September 4 丨 Kefu Healthcare (301087.SZ) recently received a survey of specific subjects on “Long-term plans and future positioning of the Jianer store?” The company replied that by the end of August, nearly 700 hearing testing and matching centers had been signed and nearly 600 had been opened. It will continue to expand at a high rate in the next 1-2 years, and strive to become the leading hearing service chain brand in China. Currently, the concentration of the hearing industry is low. Through continuous improvement of coverage and professional service capabilities, Jianear Hearing hopes to better serve consumers. At the same time, through the development of hearing testing equipment and products, the company's competitiveness will be enhanced and the cost of opening a store will be reduced.
Kefu Healthcare (301087.SZ): The respiratory support sector has a small revenue base and will achieve relatively rapid growth in the second half of this year
GLONGHUI, September 4丨Kefu Healthcare (301087.SZ) recently accepted a survey of specific subjects on “What are the profit expectations for respiratory support products?” The company replied that respiratory support is one of the categories the company is focusing on this year. In the past, the self-production ratio of products in this sector was low. The company mainly outsourced through agents and private brands, and the overall market share was low. Since the end of last year, the company has independently developed and produced products such as oxygen concentrators and nasal sprays. This year, it also launched a number of new products, boosting the growth of brand value and sales scale. As public awareness of health continues to increase, ventilators, oxygen concentrators, nebulizers, and nasal care
Kefu Healthcare (301087.SZ): In the first half of the year, it achieved revenue of 782 million yuan from self-produced products, accounting for 53.63% of main business revenue
Glonghui September 4 丨 Kefu Medical (301087.SZ) recently received a survey from a specific target, saying, “What is the current self-production ratio of products? The mid-term report that rehabilitation assistance is growing rapidly. Does the source of growth in the second half of the year depend on this?” The company replied that during the reporting period, the company achieved revenue of 782 million yuan from self-produced products, an increase of 31.17% over the previous year, accounting for 53.63% of main business revenue. The company has progressed in an orderly manner the adjustment of the production capacity structure of the two production bases in Changsha and Xiangyin and the commissioning of new products, continuously optimized the product structure, and enhanced product quality and cost advantages. In the first half of the year, income from rehabilitation aids increased
Kefu Healthcare (301087.SZ): It spent a total of about 136 million yuan to repurchase 1.77% of the shares
Glonghui, September 4, 丨Kefu Medical (301087.SZ) announced that as of August 31, 2023, the company has repurchased a total of 3,680,769 shares of the company through centralized bidding transactions through a special securities repurchase account, accounting for 1.77% of the company's current total share capital. The highest transaction price is 37.94 yuan/share, the lowest transaction price is 36.00 yuan/share, and the total transaction amount is about 136 million yuan (excluding transaction fees).
Analysis
Price Target
No Data
